Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
05 Giugno 2024 - 2:00PM
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that
the company will participate in the Goldman Sachs 45th Annual
Global Healthcare Conference on Tuesday, June 11, 2024, and will
present at 8:40 A.M. ET.
The presentation will be webcast live and may be accessed here
or by visiting Madrigal’s website’s Investor Relations Events page.
A replay of the webcast will be available after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a
biopharmaceutical company pursuing novel therapeutics for
nonalcoholic steatohepatitis (NASH), a liver disease with high
unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom),
is a once-daily, oral, liver-directed THR-β agonist designed to
target key underlying causes of NASH. For more information, visit
www.madrigalpharma.com.
Investor ContactTina Ventura, Madrigal
Pharmaceuticals, Inc., IR@madrigalpharma.com
Media ContactChristopher Frates, Madrigal
Pharmaceuticals, Inc., media@madrigalpharma.com
Grafico Azioni Madrigal Pharmaceuticals (NASDAQ:MDGL)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Madrigal Pharmaceuticals (NASDAQ:MDGL)
Storico
Da Giu 2023 a Giu 2024